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Abstract  
Hereditary hemolytic anemias are a group of disorders including red cell 
membrane defects, red blood cells enzyme disorders, congenital 
dyserythropoietic anemias, thalassemia syndromes and 
haemoglobinopathies. As damaged red blood cells passing through the 
spleen red pulp are efficiently removed by splenic macrophages, 
splenectomy is one possible therapeutic approach to the management of 
severely affected patients. However, except for hereditary spherocytosis for 
which the effectiveness of splenectomy has been well documented, the 
efficacy of splenectomy in other anemias within this group has yet to be 
determined and there are concerns regarding short- and long-term infectious 
and thrombotic complications. In light of the priorities identified by the 
European Hematology Association (EHA) Roadmap we generated specific 
recommendations for each disorder that will enable clinicians to achieve 
better informed decisions on disease management by splenectomy, on the 
type of splenectomy and possible consequences. Guidelines for thalassemia 
syndromes that have been previously established were excluded from the 
current work. As no randomized clinical trials, case control or cohort studies 
regarding splenectomy in those disorders were found in the literature, 
recommendations for each disease were based on expert opinion, which 
were subsequently critically revised and modified by the Splenectomy in Rare 
Anemias Study Group including both adult and pediatric hematologists.  
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Introduction 
Hereditary hemolytic anemias are a group of disorders including red 
cell membrane defects, enzyme disorders, congenital dyserythropoietic 
anemias, and haemoglobinopathies. Due to the rarity of these diseases 
optimal therapy has yet to be determined. Splenectomy has been suggested 
as a possible therapeutic approach to manage severely affected patients, 
based on the evidence that abnormal or damaged red blood cells passing 
through the spleen red pulp are efficiently removed by the splenic 
macrophage system. Although in recent decade splenectomy has been 
commonly used in the clinical management of patients with severe 
hematologic phenotypes, the efficacy of splenectomy in many of these 
disorders has yet to be determined. Additionally, concern remain regarding 
short- and long-term infectious complications, and increased risk of 
cardiovascular complications in later life, including thrombosis and pulmonary 
hypertension.1 
We first reviewed the literature in PubMed in order to generate 
recommendations for splenectomy in these disorders. No randomized clinical 
trials, case control or cohort studies were identified lowering the level of 
evidence to non-analytic studies and case series. Expert recommendations 
were developed, and subsequently critically revised and modified by the 
Splenectomy in Rare Anemias Study Group in order to achieve the highest 
possible agreement that was classified as "full consensus” (100%) 
agreement or “consensus” (>80%). None of the core statements achieved a 
degree of consensus below 80%. The Grading of Recommendation 
Assessment, Developing and Evaluation (GRADE) system was used to rate 
quality of evidence and strength of recommendations (see supplementary 
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document).2 
In the present manuscript, we first present possible general 
complications of splenectomy including, post splenectomy infections and 
thromboembolic complications, then discuss the advantages and 
complications of splenectomy for each of the specific hereditary hemolytic 
anemia disorders prior to generating specific recommendations. 
Splenectomy Complications 
Post Splenectomy Infections 
Due to the role of the spleen in immune competence and blood 
filtration, post splenectomy there is a risk of overwhelming infection (OPSI) 
which is highest with encapsulated organisms such as S. pneumoniae, 
N.meningitis and H. influenza.3 Asplenia is also an important risk factor for 
serious infection with Plasmodium, Capnocytophaga canimorsus and 
cynodegmi (after an animal bite), Babesia (after a tick bite), and Bordetella 
holmesii.4-6 The risk of post-splenectomy sepsis may vary according to the 
indication for splenectomy [intermediate for spherocytosis and higher for 
other inherited anemias],7 patient’s age at the time of surgery [highest before 
age of 5],3 and interval since splenectomy was performed [highest during the 
first year]. However, an elevated risk probably remains for life.8,9 Due to the 
high risk of OPSI at a young age, splenectomy should not normally be 
performed before 5 years of age. 
It is difficult to estimate the current risk of OPSI at age >5 years as 
most studies are retrospective and include patients with heterogeneous 
diseases who were not fully immunized. It is possible that the wide use of 
conjugated vaccines will significantly reduce the risk of OPSI. In fact, a recent 
retrospective study analyzing 141 consecutive children undergoing 
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splenectomy during 1991-2010 suggested that 10 of 11 patients suffering 
from post-splenectomy sepsis had an additional underlying immune 
deficiency.10 However, in a recent prospective multicenter cohort study of 
German patients, who underwent splenectomy due to variety of causes, S. 
pneumoniae sepsis was more frequent than in patients with a normal 
functional spleen (42% vs 12% respectively; P < .001). It is of note that less 
than half of the OPSI patients in the above study received pneumococcal 
vaccination before splenectomy, despite national and international 
guidelines.11 
Strategies to reduce the risk of OPSI include: (i) patient’s education 
including urgent action in response to febrile episodes; (ii) vaccination and 
(iii) prophylactic anti-microbial therapy. As detailed guidelines regarding 
prevention and treatment of infections in splenectomized or asplenic patients 
are available through the British Committee for Standards in Haematology12 
and American Academy of Pediatrics (Red Book 30th edition, 2015), the 
reader is referred to those publications for detailed instructions. 
 
Post Splenectomy Thromboembolic Complications  
An increased risk of early and late venous and arterial thrombosis was 
described after splenectomy,1,13 including acute splenic and portal vein 
thrombosis (SPVT)14 and delayed severe life-long complications.15 
Acute Splenic and Portal Vein Thrombosis  
Acute splenic and portal vein thrombosis (SPVT) after splenectomy is 
an early and life-threatening complication, which can lead to bowel ischemia 
and/or portal hypertension. These complications have been related to stasis 
in splenic vein remnant.14 The risk varies with the underlying disorder. Krauth 
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et al in 2008 compiled prospective and retrospective studies and found that 
11/89 patients with hemolytic disease developed SPVT (12.3%) while only 
2/118 patients (1.7%) of those with immune thrombocytopenia had SPVT. 
None of 122 patients who underwent splenectomy due to trauma developed 
this complication.14,15 Large spleen size has also been identified as a risk 
factor for the development of SPVT. Although there are no well-designed 
randomized trials comparing the risk for SPVT after open splenectomy (OS) 
versus laparoscopic splenectomy (LS), the surgical approach seems not to 
affect incidence of SPVT.16 Screening for thrombophilia has not been shown 
to allow early identification of patients at risk for SPVT after splenectomy.17 
A study with contrast-enhanced CT used for the diagnosis of SPVT 
showed a median time of 6 days (range 3-11 days) between splenectomy 
and the appearance of asymptomatic SPVT.18 A Canadian study of 40 
patients suggested that the timing for SPTV Doppler/ultrasound surveillance 
to diagnose SPVT is one week following splenectomy.19 
Most patients with documented SPVT were treated with anticoagulant 
therapy (i.e. intravenous heparin followed by oral anticoagulants) for a 
variable time period ranging between 3 to 6 months. A documented complete 
(57/90, 63.3%) or at least partial resolution (13.3 %) of the thrombus was 
reported in the majority of treated patients. However, 7.7% of this latter 
population showed persistence of thrombus, while 15.5% developed a 
cavernoma or portal hypertension.14 
The role of prophylactic antithrombotic therapy is unknown as 
strategies in the various cohorts or case reports were extremely 
heterogeneous in terms of duration of prophylaxis. A randomized study 
comparing different durations of postoperative thrombosis prophylaxis after 
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laparoscopic abdominal surgery was terminated early due to the low 
incidence of thrombosis.16 
Late Vascular Events 
 
Arterial and Venous Thromboembolism  
An increased risk of vascular complications after splenectomy was first 
described in a group of 740 World War II veterans whose spleen was 
removed for trauma. A significantly increased risk of death from ischemic 
heart disease compared to controls was described with a relative risk of 
1.85.15 Data from a Danish Registry identifying all splenectomized patients 
from 1996-2005 showed that the long-term (>1 year) risk of venous 
thromboembolism (VTE) remained approximately 3-fold higher in trauma 
patients undergoing splenectomy versus the general population.20 However, 
the contribution of other trauma complications to thrombotic risk was not 
evaluated. The long-term risk was highest in patients splenectomized for 
malignant hematological disorders and hemolytic anemias. 
Pulmonary Arterial Hypertension  
Splenectomy has been reported to be a risk factor for the development 
of pulmonary arterial hypertension (PAH),21 particularly in patients with 
hemolytic disorders.22-24 Loss of splenic function is associated with increased 
number of platelets and also increases in their activation, promoting 
pulmonary microthrombosis and red cell adhesion to the endothelium.25 The 
spleen also plays a critical function in the removal of senescent and 
damaged erythrocytes.  
Splenectomy Recommendations  
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-For prompt diagnosis of SPVT at least one Doppler ultrasound study 
should be carried out on day 7 post-splenectomy (agreed by 86% of 
experts) (Grade 2 recommendation, grade C evidence). 
 
Surgical Approach 
Laparotomy Splenectomy  
The traditional approach to splenectomy has been by laparotomy. This 
approach allows for a careful search for an accessory spleen that if left 
behind may cause recurrence of anemia.10 The disadvantages of open 
splenectomy OS are mainly surgical morbidity and abdominal wall scarring.26 
LS has become feasible with progress in minimally invasive techniques.27 
Laparoscopic Splenectomy 
Currently LS is considered the gold standard for normal size or slightly 
enlarged spleen and is preferred to OS. LS (i) is less traumatic; (ii) presents 
fewer complications; (iii) requires shorter hospital stays; (iv) has better 
cosmetic outcome, and an overall lower cost compared to OS. However, it 
should be performed only by experienced operators.28 Nowadays, 
splenectomy is possible and safe also for massively enlarged spleen, but is 
associated with longer operative time and hospital stay.29 Perioperative 
splenic artery embolization was also found to be useful and lower the 
complications of massive spleen LS.30 Moreover, selective splenic artery 
embolization, carried out in steps, will reduce spleen size and alleviate 
cytopenias.31  
A pre-operative assessment of splenic size by ultrasound is 
recommended. Although three dimensional CT scan is considered to be 
more accurate, it does not provide significant advantage in estimating spleen 
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size and its use should be limited to those cases where additional information 
about the anatomy is required prior to surgery.32 
Partial Splenectomy  
In an attempt to reduce the infectious risk of total splenectomy, 
especially for children less than 6 years of age who suffer severe anemia or 
are transfusion-dependent, partial splenectomy (PS) has been increasingly 
used in recent years. In PS, 80-90% of the enlarged spleen is generally 
removed. PS was initially performed using an OS approach but laparoscopic 
and robotic approaches have recently been introduced.33 Nevertheless, PS 
should always be performed by an experienced surgeon. 
Disease Specific Recommendations 
A detailed discussion of the clinical picture and diagnostic approaches 
to hereditary hemolytic disorders is beyond the scope of this manuscript. 
Data available on the advantages and complications of splenectomy in 
hereditary hemolytic anemias and expert recommendations are summarized 
in Table 1. It should be appreciated that for some disorders data is so sparse 
and that no recommendations could be generated. 
Hereditary Spherocytosis 
General 
Following thalassemia syndrome and sickle cell disease (SCD), 
hereditary spherocytosis (HS) is the most common form of congenital 
hemolytic anemia with an incidence of approximately 1:2000 and a dominant 
transmission in about 70-80% of cases. HS is caused by mutations in genes 
encoding for α- and β-spectrin and in genes encoding other proteins involved 
in the attachment of cytoskeleton to the overlying lipid bilayer (ankyrin, band 
3 and protein 4.2). Defects in these structural proteins render the RBC 
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spherical, rigid and susceptible to premature destruction in the spleen.34-
37Clinically, patients with HS are grouped into 3 categories according to the 
disease severity: mild, moderate and severe (Table 2).36  
Long Term Thrombotic Complications of Splenectomy in Hereditary 
Spherocytosis 
Schilling in 1997 found that the rate of arteriosclerotic events (stroke, 
myocardial infarction, coronary or carotid artery surgery) in patients older 
than 40 years of age with HS, was 5.6 fold higher in asplenic patients 
compared to HS patients with intact spleen, with the first event occurring one 
or more decades following splenectomy.38 This was further confirmed in his 
follow-up study in which arterial events in HS patients, had a hazard ratio of 
7.2 compared to affected patients who did not undergo splenectomy. In 
addition, affected patients who underwent splenectomy had a hazard ratio of 
3 for developing of venous events as compared to HS patients who did not 
undergo splenectomy. 39 
However, only few patients with HS who developed stroke, PE or PAH 
following splenectomy have been reported.24,40-42 Moreover, Buchanan et al 
studied 39 adults with HS and found no evidence for thrombotic 
manifestations despite a long follow up (median 25 years).43 
Splenectomy in Hereditary Spherocytosis 
Splenectomy in HS usually results in disappearance of anemia and 
clear decrease of hemolytic markers. In the large HS series reported by 
Mariani et al the median hemoglobin increase after splenectomy was 3 g/dL 
(10.8 to 13.9 g/dL), associated with a decrease of reticulocyte count (from 
337 to 51×109/L) and unconjugated bilirubin (from 32.5 to 12 µmol/L).44 
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Due to increasing awareness to post splenectomy complications, in 
the past decade the rate of splenectomy continues to declined. During 1980-
2005, splenectomy was performed in only 20% of HS patients.44 In general, 
splenectomy is not indicated in patients with mild HS, whereas it is usually 
necessary in severe cases, albeit delayed if possible until the age of 6 years 
(Table 2). In the intermediate categories the indications for splenectomy are 
less clear, one indication is symptomatic/painful splenomegaly with 
associated thrombocytopenia or leukopenia that impacts the patient’s quality 
of life. For young adult patients, unacceptable cutaneous icterus (usually in 
patients with concomitant Gilbert genotype) may become a social problem 
that balances a decision towards splenectomy. 
Available Guidelines for Splenectomy in Hereditary Spherocytosis 
Guidelines for the diagnosis and management of HS, including 
splenectomy were published on behalf of the General Haematology Task 
Force of the British Committee for Standards in Haematology in 2004 and 
updated in 2011.45-46 In agreement with previous recommendations, the 
laparoscopic approach is preferred if trained surgeons are available, in 
children undergoing splenectomy, the gall bladder should be removed 
concomitantly if symptomatic gallstones are present (Table 3). We refer to 
previously published guidelines asking if: (1) splenectomy should accompany 
cholecystectomy when biliary stones are present and (2) partial splenectomy 
be performed for children younger than 6 years of age with severe HS. 
Should Splenectomy Accompany Cholecystectomy 
It was previously suggested that there is an increased risk of 
intrahepatic choledocholithiasis following splenectomy44 and the 2004 
guidelines suggested that for children with HS who require cholecystectomy 
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the spleen should always be removed.45 This recommendation was based on 
expert opinion despite little supportive data in the literature thereafter, the 
recommendation was changed in subsequent guidelines to indicate that this 
issue remains controversial.46 In a recent study, of 32 pediatric patients with 
HS who underwent cholecystectomy, 27 underwent synchronous 
splenectomy. However, none of the five patients who underwent 
cholecystectomy without splenectomy experienced signs or symptoms 
consistent with biliary stones over a median follow-up of 15.6 years.47 
Similarly, in a recent study of children aged 4-17 years studied during 2009-
2012, simultaneous cholecystectomy (for cholelithiasis) and splenectomy 
were performed in fewer than half of the patients.48 We recommend that 
indications for splenectomy when cholecystectomy is required should not 
differ from that for splenectomy with no cholecystectomy (Tables 1,2). 
Partial Splenectomy 
In an attempt to reduce the infectious risk of total splenectomy, 
especially for children less than 6 years of age who suffer severe anemia or 
are transfusion-dependent, partial splenectomy (PS) has been increasingly 
performed in recent years. Several studies indicate that partial splenectomy 
reduces the hemolytic rate and increases red cell lifespan while maintaining 
efficient splenic phagocytic function.49-50 In a recently published follow-up 
study, Pincez et al. reported on 79 HS children who underwent partial 
splenectomy using an OS approach during 1985-2013. In this population, 39 
children were less than 5 years of age at time of splenectomy (mean age at 
surgery 4.3±0.6 years) and most were transfusion–dependent (31/39). 
Following PS (mean follow up of 12±0.9 years) there was a drastic reduction 
in transfusion rate and increase in hemoglobin levels that were compatible 
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with normal growth while maintaining efficient spleen function in 96% of 
cases.51 On the other hand, this approach reduced but did not totally 
suppress hemolysis and was associated with later development of biliary 
stones, and splenic remnant regrowth. Finally, 50% of the 39 severely 
affected young HS children required total splenectomy in a median of 5 years 
following PS at an age when total splenectomy was much safer.51 Drop in 
hemoglobin levels and discomfort due to spleen remnant regrowth were the 
most common indications for this procedure. A recently published systematic 
review and meta-analysis comparing HS patients undergoing total (1941 HS 
children) versus partial splenectomy (283 HS children), confirmed that 
although total splenectomy was more effective than PS in increasing Hb 
levels (3.6g/dl compared to 2.2g/dl, respectively) and in reducing reticulocyte 
counts (12.5% compared to 6.5% respectively), the outcome following PS 
was stable for at least 6 years. There were no cases of OPSI.52 In this meta-
analysis, with overall short follow-up length, recurrence of symptoms in PS 
was uncommon (5-10%) and secondary splenectomy was indicated in only 
5% of children. Thus, partial splenectomy still needs to be evaluated in larger 
series with longer term follow-up. In view of these conflicting data no 
recommendation regarding PS in HS could have been generated by the 
group. 
Splenectomy Recommendations  
- Splenectomy is recommended in HS patients who are 
transfusion-dependent or suffer severe anemia (agreed by 100% of 
experts) (Grade 2 recommendation, grade C evidence). 
-Indications for splenectomy in the intermediate forms of HS 
should be individually tailored based on spleen size and quality of life 
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parameters (agreed by 95% of experts) (Grade 2 recommendation, 
grade C evidence). 
 
Pyruvate Kinase Deficiency 
General 
Pyruvate kinase deficiency (PKD) is the most common glycolytic 
defect causing congenital non‐spherocytic hemolytic anemia (CNSHA) with 
incidence of 1:20,000 in white individuals.53 Pyruvate kinase converts 
phosphoenolpyruvate to pyruvate, generating 50% of the red cell total ATP. 
PK deficiency red blood cells, are damaged due to lack of energy to support 
membrane ion transport, and to maintain membrane structure and are 
therefore cleared by the spleen and liver. Clinically, PKD has been 
categorized into mild, moderate and severe forms (Table 4).54-55  
Results of Splenectomy in Pyruvate Kinase Deficiency 
Small retrospective studies suggest that splenectomy may result in a 
moderate increase in hemoglobin levels of approximately 1.8 g/dl (range 0.4–
3.4), together with a conspicuous rise of reticulocytes (up to 50-70%, a 
typical feature of PK deficiency) and increased amounts of indirect bilirubin, 
even if the anemia becomes less severe.54 Analysis of the results of a recent 
international, multicenter registry study with 144 patients,56 suggested that 
splenectomy was performed mainly to reduce transfusion burden and 
resulted in improved anemia, and thus enhanced quality of life. The median 
pre-splenectomy hemoglobin was 7 g/dl and, surgery reduced the transfusion 
burden in 91% of cases. Fifty-three patients (66%) underwent 
cholecystectomy at a median age of 14 years (2.6-60.4), of whom a 
splenectomy had been performed in 35 (37%). Importantly this study showed 
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that transfusion-dependency and moderate anemia persisted despite 
splenectomy in more than half of the patients, suggesting that surgery is less 
effective in PK deficiency than in HS. 
Indications for Splenectomy in pyruvate Kinase Deficiency 
Splenectomy may be beneficial in patients with high transfusion 
requirements. It may also be considered in patients with low transfusion 
requirements who may subsequently become transfusion independent 
following splenectomy, although this is difficult to predict. It does not arrest 
hemolysis, however, it reduces and sometimes eliminates the transfusion 
requirement in most transfusion-dependent cases. The response to surgery 
of other affected family members may help in predicting the therapeutic 
efficacy of splenectomy.54,55 Optimal timing of surgery is unclear and needs 
to be considered individually weighing up the life-long risks (infection, 
thromboembolism) against the likely benefits. 
Cholecystectomy and Splenectomy pyruvate Kinase Deficiency 
As for HS, splenectomy should also be considered in patients 
requiring cholecystectomy to avoid a second surgery. However, in contrast to 
HS in PK deficiency gallstones are also common in splenectomized patients, 
and therefore cholecystectomy should accompany splenectomy.  
Partial Splenectomy in pyruvate Kinase Deficiency  
Partial splenectomy was reported to be unsuccessful in two PK 
deficient cases, and effective in one patient with an increase in the baseline 
hemoglobin and reduction in transfusion rate.57 
Other therapeutic options for PK deficiency that should be considered 
include HLA-matched sibling allogeneic transplant,58 and new therapies 
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which are still under investigation including the enzyme activator (AG-348)59 
and gene therapy.60 
 
Splenectomy Recommendations  
-Splenectomy should be considered in patients with PK who are 
transfusion-dependent or do not tolerate the anemia (agreed by 91% of 
experts) (Grade 2 recommendation, grade C evidence). 
-Cholecystectomy should be performed together with splenectomy 
(agreed by 86% of experts) (Grade 2 recommendation, grade C 
evidence). 
 
Congenital Non-Spherocytic Hemolytic Anemia due to G-6PD 
Deficiency  
G6PD deficiency patients rarely suffer hemolytic anemia in the steady 
state when not triggered by an exogenous factor. Some mutations of G6PD 
result in chronic hemolysis without precipitating causes. These mutations are 
more severe than the more commonly occurring polymorphic forms of the 
enzyme. The severity of anemia ranges between borderline to transfusion-
dependent. Hamilton et al (2004) identified nine transfusion-dependent 
patients in the literature, seven responded to splenectomy and became 
transfusion-independent.61 Luzzatto and Poggi suggested that splenectomy 
should be performed if splenomegaly becomes a physical encumbrance, or if 
there is evidence of hypersplenism and if the anemia is severe.62 
Splenectomy Recommendation 
-Splenectomy should be considered in patients with congenital non-
spherocytic hemolytic anemia due to G6PD deficiency, who are 
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transfusion-dependent and/or have symptomatic splenomegaly. 
(Agreed by 100% of experts) (Grade 2 recommendation, grade C 
evidence) 
 
 
 
Pyrimidine-5’-nucleotidase Deficiency  
Deficiency of erythrocyte P5’N is the most common inherited 
abnormality of nucleotide metabolism causing hemolytic anemia of moderate 
severity.55,63 Transfusions are rarely required. Splenectomy has been 
associated with variable increase in hemoglobin levels.64-67 
Portosplenomesentric venous thrombosis was described in one P5’N patient 
following splenectomy due to trauma.68 As there is insufficient data regarding 
efficacy and complications of splenectomy in this disorder no 
recommendations could be given.  
 
Hereditary Stomatocytosis  
Hereditary stomatocytosis (HSt) is a dominant disorder comprising both 
dehydrated (DHS) and overhydrated (OHS) types, which show alteration of 
the RBC membrane permeability to monovalent cation (Na+ and K+), with a 
consequent alteration in the intracellular cationic content and in red cell 
volume. DHS is the most highly represented among HSt disorders, with an 
incidence of approximately 1:50000 births. OHS is a very rare subtype 
among HSt disorders, with only 20 cases reported worldwide. The recent 
identification of genes mutated in HSt has improved diagnosis and 
understanding of the pathophysiology of this group of disorders. To date, a 
18 
 
total of five different genes encode for membrane proteins have been 
reported to be responsible for RBC volume alterations, three leading to OHSt 
(AE1 [also termed SLC4A1], RHAG and GLUT1 [also termed SCL2A1) 69,70 
and two to DHSt (PIEZO1 and the Gardos Channel)71-75. Reviews on the 
clinical picture and molecular pathogenesis have recently been 
published.37,76.  
 
Splenectomy in Hereditary Stomatocytosis 
High risk of thromboembolic complications following splenectomy in 
hereditary stomatocytosis was first described by Stewart and colleagues 
(1996) in nine splenectomized adults.77 In their seven families four had OHSt 
and the remaining DHSt. Both groups suffered from serious late thrombotic 
complications, sometimes recurrent over years, including DVT, pulmonary 
emboli (PE), superficial thrombophlebitis, portal vein thrombosis, intracardiac 
mural thrombosis, arterial thrombosis, and PAH. Four of the nine patients 
died. No such complications were observed in six affected before 
splenectomy. Since this original observation there have been at least four 
additional reports of individuals with OHSt or DHSt who developed severe 
thrombotic complications.78-81  
Given the retrospective, incomplete, and anecdotal nature of the 
description of thromboembolic complications following splenectomy in HSt it 
is impossible to estimate the precise risk of this procedure, but it is apparent 
that there is a high risk and that splenectomy, which is only partially effective 
in OHSt and ineffective in DHSt, should be avoided. In patients with 
hereditary stomatocytosis who were mistakenly misdiagnosed as HS and 
underwent splenectomy life-long anti-coagulation should be considered. 
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Splenectomy Recommendations  
- In patients with hereditary stomatocytosis splenectomy is contra-
indicated (agreed by 100% of experts) (Grade 2 recommendation, grade 
C evidence). 
 
 
 
Congenital Dyserythropoietic Anemia 
Congenital dyserythropoietic anemia (CDA) is a group of rare red 
blood cell disorders characterized by ineffective erythropoiesis, 
pathognomonic cytopathology of nucleated red blood cells in bone marrow 
and increased iron absorption with secondary hemochromatosis.82 Based on 
morphological criteria, subsequently supported by genetic analysis, three 
types have been described (I-III). More recently CDA IV was defined and 
several additional unclassified patients have been characterized.83 CDA II is 
the most common subtype, with more than 200 patients described in the 
literature followed by CDA I with approximately 100 patients.82 
Splenectomy in CDA I 
Two case series of 13 severely anemic mostly transfusion-dependent 
patients undergoing splenectomy were identified, who had undergone 
splenectomy.84,85 Six of those patients became transfusion-independent 
following splenectomy, while seven had no improvement in hemoglobin 
levels. Long-term follow-up of six patients revealed that three had died one 
due to PAH and the other two due to overwhelming sepsis. Because of 
inconsistent response and possible complications, splenectomy should 
probably be reserved for patients manifesting worsening anemia, and/or 
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significant thrombocytopenia or leukopenia or for patients with massive 
painful splenomegaly. Due to paucity of data no recommendation regarding 
splenectomy is CDA I could be generated. 
CDA II 
Heimpel at al reported on 22 patients who underwent splenectomy at a 
median age of 19.9 years.86 Hemoglobin concentration improved in all 
patients from an average of 9.2 g/dl to 10.3 g/dl. However, in all but one 
patient, hemoglobin levels remained below sex-matched reference values.86 
Russo et al reported that 36% (41/112) of their patients with CDAII 
underwent splenectomy and most (14/17) showed a similar moderate 
increase in hemoglobin concentration (9.3±1.2 g/dl to 10.6±1.6 g/dl).87 To 
date thrombosis has not been documented in patients with CDA II following 
splenectomy.  
Splenectomy Recommendations  
-In patients with CDA II splenectomy should be considered in severely 
anemic patients and/or in those with symptomatic splenomegaly 
(agreed by 95% of experts) (Grade 2 recommendation, grade C 
evidence). 
 
Hemoglobinopathies 
The authors decided not to discuss thalassemic syndromes since 
revised guidelines have recently been presented by TIF (please visit: 
www.tif.org).88 
Sickle Cell Disease (SCD)  
Sickle Cell Disease (SCD) is a worldwide distributed hereditary red cell 
disorder with an annual birth rate of 237,381; 11,143; and 1,939 in Africa, US 
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and Europe respectively.89 SCD is caused by a point mutation in the β-globin 
gene resulting in the synthesis of pathological hemoglobin S (HbS).90 Cyclic 
polymerization/depolymerization of deoxy-HbS generate dense, dehydrated 
red cells, playing a central role in acute and chronic clinical manifestations of 
SCD, in which intravascular sickling leads to vaso-occlusion (VOCs) and 
impaired blood flow with ischemic/reperfusion injury.90 Some organs, such as 
the spleen, have been shown to be more vulnerable to damage from HbS 
polymerization than others organs, due to their peculiar anatomic 
organization mainly characterized by sluggish circulation, low pH and local 
high pro-oxidant environment.90,91  
Splenectomy in Sickle Cell Disease 
Acute splenic sequestration crisis (ASSC) is defined as acute 
abdominal pain and distension associated with spleen enlargement, a decline 
in Hb levels of at least 2 g/dL and stable or high reticulocyte count compared 
to patient in steady state.92 Even though the mortality rate of SCD patients 
has declined since the introduction of neonatal screening for SCD, 
vaccination program and parental education, ASSC is still a life-threatening 
complication.93 The clinical management of ASSC with acute splenic sickling 
and spleen blood entrapment, is based on rapid correction of hypovolemic 
shock by crystalloid and packed red cell infusion. Although international 
guidelines or consensus are not available for management of ASSC, 
splenectomy is usually recommended after two ASSC episodes requiring 
urgent transfusion.92-95 
Hypersplenism, defined as chronic splenic enlargement with 
decreased hemoglobin, platelet and leukocyte count, is the second major 
indication for splenectomy in SCD patients.92-95 Splenectomy is usually 
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indicated if there is hypersplenism, pressure effects of the spleen or failure to 
thrive. Transfusion is often ineffective in such children due to RBC 
sequestration in the enlarged spleen. 
Although splenectomy is the treatment for either recurrent ASSC or 
hypersplenism in SCD, there is no evidence that it improves the hemoglobin 
level, decrease the hemolysis or increases patient survival.96 In addition, 
splenectomy may increase thromboembolism. Limited evidence is available 
about any possible increased incidence of PAH or pain frequency in SCD 
patients.97 
In SCD children LS is generally used, after preoperative transfusion or 
exchange transfusion to decrease the HbS percentage.  In SCD children, the 
major limitations for using a laparoscopic approach are the spleen size with 
its local adhesion and the longer length of operative time. Although LS has 
some positive aspects such as the shorter duration of hospitalization, its 
impact on the incidence of post-operative SCD-related severe acute 
complication, such as acute chest syndrome (ACS), is still unclear.98,99 To 
date there are no real advantages in terms of hematologic phenotype and 
infective risk to partial splenectomy as compared to total splenectomy in SCD 
children.100 
Thus, in SCD guidelines on clinical management for ASSC are needed, 
that present parameters and the timing for splenectomy, with accompanying 
surgical approaches. Indications are likely to vary depending on 
environmental factors, including the availability of safe blood transfusion and 
the spectrum of infection. Future multicenter studies should be designed to 
address these questions. 
Splenectomy Recommendations  
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-In SCD children, splenectomy is recommended after two episodes of 
ASSC (agreed by 100% of experts) (Grade 2 recommendation, grade C 
evidence). 
-In SCD children, splenectomy is also recommended in patients with 
massive splenomegaly and/or hypersplenism (agreed by 90% of 
experts) (Grade 2 recommendation, grade C evidence). 
 
Unstable hemoglobin 
Globin mutations that destabilize hemoglobin tetramers constitute a 
very rare cause of hemolytic anemia. The clinical pattern of hemolytic anemia 
related to unstable hemoglobin is extremely variable. Severely affected 
patients particularly those with hyperunstable hemoglobin present early in 
childhood and may require chromic transfusion therapy. Following 
splenectomy thrombotic complications were described in nine patients (with 
Hb Bridlington/HbTaybe, Hb Taybe, Hb Mainz, Hb Olmsted, Hb Madrid and 
Hb Perth).101-106 Thrombotic events including PE, PAH, arterial stroke and 
priapism occurring even 4-32 years after splenectomy have been described 
in all reported patients. Moreover, the majority of patients (7/9) had no 
improvement or only partial improvement in hemoglobin levels. Despite the 
anecdotal data splenectomy should be considered only when there is severe 
anemia and/or of massive or symptomatic splenomegaly.   
Splenectomy Recommendations  
-In patients with unstable hemoglobin splenectomy should be 
considered when the spleen is very large and/or there is evidence of 
hypersplenism (agreed by 95% of experts) (Grade 2 recommendation, 
grade C evidence).  
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Table 1: Summary of splenectomy recommendations for hemolytic 
disorders 
Disease  When is splenectomy 
recommended? * 
Hereditary spherocytosis Patient is transfusion-dependent or 
suffers severe anemia. 
Patient has moderate disease-
decision based on spleen size and 
quality of life parameters. 
No need to perform cholecystectomy. 
Pyruvate kinas deficiency Consider if patient is transfusion-
dependent or severely anemic. 
Cholecystectomy should be 
performed at time of splenectomy. 
Splenectomy in congenital non-
spherocytic hemolytic anemia due to 
G6PD deficiency 
Considered if patient is transfusion-
dependent and/or has massive 
splenomegaly and/or has 
symptomatic splenomegaly. 
Hereditary stomatocytosis Contra-indicated. 
Congenital dyserytrhopoietic anemia 
type II 
Considered if patient is transfusion-
dependent and/or has symptomatic 
splenomegaly. 
Sickle cell disease Patient had two episodes of acute 
splenic sequestration crisis and/or 
has massive splenomegaly and/or 
suffers symptomatic hypersplensim. 
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Unstable hemoglobin Considered only if patient is 
transfusion-dependent anemia and/or 
symptomatic splenomegaly. 
*For all indications splenectomy should be performed after 6 years of age. 
 
Table 2: Indications for splenectomy in HS based on severity of 
disease*  
Disease 
severity 
Hemoglobin 
level (gr/dL) 
Reticulocyte 
counts (%) 
Bilirubin 
(µmol/l) 
Indication for 
splenectomy  
Severe < 8 > 10 > 51 Indicated, delayed 
until age >6 years 
Moderate 8 - 12 > 6 > 34 Individually tailored 
based on spleen 
size and quality of 
life parameters 
Mild 11 - 15 3 - 6 17 - 34 Not indicated 
*severity of disease based on reference 35 
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Table 3: Splenectomy guidelines in hereditary spherocytosis –2011 
update* and authors’ recommendations 
No. Guidelines 2011  Authors' 
recommendations 
1 The laparoscopic approach to splenectomy is 
associated with less pain, shorter hospital stay and 
better cosmetic appearance; but is dependent on 
the availability of appropriately trained surgeons, 
and suitable equipment (grade 1 recommendation, 
grade B evidence). 
No change. 
2 In children undergoing splenectomy, the gall 
bladder should be removed concomitantly if there 
are symptomatic gallstones (grade C evidence, 
grade 2 recommendation). 
No change. 
3 In children who require cholecystectomy for 
symptoms of gallstones the use of concurrent 
splenectomy is controversial. It may be associated 
with a decreased risk of common bile duct stones in 
the future, but is also associated with a risk of post-
splenectomy sepsis (grade 2 recommendation, 
grade C evidence). 
In children > 6 
years of age 
concomitant 
splenectomy is 
indicated 
according to 
severity of 
anemia (Table 1).  
4 When splenectomy is indicated, ideally it should be 
done after the age of 6 years (grade 2 
recommendation, grade C evidence). 
No change. 
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5 Partial splenectomy is theoretically associated with 
a decreased risk for post-splenectomy sepsis, but it 
is possible that further surgery may be needed for 
either recurrence of hematological problems or 
symptomatic cholelithiasis (grade 2 
recommendation, grade C evidence). 
No consensus 
among our 
experts. 
* Reference 45 
The Grading of Recommendation Assessment, Developing and Evaluation 
(GRADE) system was used to rate quality of evidence and strength of 
recommendations. 
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Table 4: Indications for splenectomy in pyruvate kinase deficiency 
based on severity of disease*  
Diseas
e 
severit
y 
Age at 
diagnosis 
Clinical 
manifestatio
ns  
Median 
Hemoglob
in (g/dl) 
Transfusio
n 
requireme
nt 
Indication 
for 
splenecto
my 
Severe Birth/infan
cy  
Most patients 
suffer severe 
neonatal 
jaundice 
requiring 
exchange 
transfusion, 
median age 
at diagnosis 
4, almost all 
transfusion-
dependent  
6.8 Transfusion
-dependent 
Indicated 
after age>6 
Modera
te 
Variable, 
childhood 
to adult 
Moderate 
anemia 
occasional 
exacerbation
s 
9 Confined to 
exacerbatio
ns 
Not 
indicated  
Mild Variable, 
childhood 
Long live 
history of 
11 Rare Not 
indicated 
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to adult mild anemia 
Severity of disease based on references 54, 55. 
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Supplementary document 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) (2) 
Strength of Recommendation 
Strong recommendations (grade 1): the evidence is high quality and the desirable effect 
clearly outweigh the undesirable effect.  
Weak recommendations (grade 2): There is a close or uncertain balance 
The quality of evidence  
(A) High: Further research is very unlikely to change confidence in the estimate of effect. 
Current evidence derived from randomized clinical trials without important limitations. 
(B) Moderate: Further research may well have an important impact on confidence in the 
estimate of effect and may change the estimate. Current evidence derived from 
randomized clinical trials with important limitations. 
 (C) Low: Further research is likely to have important impact on confidence in the estimate 
of effect and is likely to change the estimate. Current evidence from observational studies, 
case series or just opinion.  
 
